Stemline Therapeutics Inc (NASDAQ:STML) Receives Consensus Recommendation of “Buy” from Brokerages

Share on StockTwits

Stemline Therapeutics Inc (NASDAQ:STML) has been assigned an average recommendation of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $25.00.

Several research firms recently issued reports on STML. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stemline Therapeutics in a report on Monday, September 30th. Zacks Investment Research lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 7th. Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, September 18th. ValuEngine lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, September 11th. Finally, BidaskClub lowered shares of Stemline Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 10th.

In other news, CEO Ivan Bergstein sold 35,010 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $14.73, for a total transaction of $515,697.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 13.10% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in shares of Stemline Therapeutics by 16.6% in the 2nd quarter. BlackRock Inc. now owns 3,152,812 shares of the biopharmaceutical company’s stock worth $48,301,000 after acquiring an additional 449,323 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Stemline Therapeutics by 14.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,933,455 shares of the biopharmaceutical company’s stock worth $29,620,000 after acquiring an additional 237,768 shares during the last quarter. C WorldWide Group Holding A S raised its holdings in shares of Stemline Therapeutics by 139.6% in the 2nd quarter. C WorldWide Group Holding A S now owns 858,082 shares of the biopharmaceutical company’s stock worth $13,146,000 after acquiring an additional 500,000 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Stemline Therapeutics by 1.8% in the 2nd quarter. Northern Trust Corp now owns 523,341 shares of the biopharmaceutical company’s stock worth $8,017,000 after acquiring an additional 9,112 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its holdings in shares of Stemline Therapeutics by 196.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 518,870 shares of the biopharmaceutical company’s stock worth $7,949,000 after acquiring an additional 343,870 shares during the last quarter. Institutional investors own 82.46% of the company’s stock.

STML stock traded up $0.01 during midday trading on Friday, hitting $9.03. The stock had a trading volume of 402,814 shares, compared to its average volume of 628,044. The firm has a market cap of $396.92 million, a P/E ratio of -3.02 and a beta of 1.41. The company has a current ratio of 4.71, a quick ratio of 4.57 and a debt-to-equity ratio of 0.01. Stemline Therapeutics has a 1-year low of $7.82 and a 1-year high of $18.22. The business has a fifty day moving average price of $10.45 and a two-hundred day moving average price of $13.35.

Stemline Therapeutics (NASDAQ:STML) last released its earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.05. The firm had revenue of $13.01 million during the quarter, compared to analyst estimates of $8.84 million. On average, equities analysts anticipate that Stemline Therapeutics will post -1.92 EPS for the current year.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Story: Convertible Shares

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Short Interest in Boston Beer Company Inc  Drops By 11.2%
Short Interest in Boston Beer Company Inc Drops By 11.2%
Smartsheet Inc  Short Interest Update
Smartsheet Inc Short Interest Update
Nabtesco  Cut to “Sell” at Zacks Investment Research
Nabtesco Cut to “Sell” at Zacks Investment Research
Magenta Therapeutics  Rating Reiterated by Cowen
Magenta Therapeutics Rating Reiterated by Cowen
Trevi Therapeutics  Receives Buy Rating from Needham & Company LLC
Trevi Therapeutics Receives Buy Rating from Needham & Company LLC
IAA  Stock Rating Upgraded by CJS Securities
IAA Stock Rating Upgraded by CJS Securities


© 2006-2019 Ticker Report